11.49
0.24 (2.13%)
| Previous Close | 11.25 |
| Open | 11.56 |
| Volume | 1,013,037 |
| Avg. Volume (3M) | 2,558,049 |
| Market Cap | 1,321,648,768 |
| Price / Earnings (Forward) | 11.96 |
| Price / Sales | 0.520 |
| Price / Book | 1.25 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| Profit Margin | -2.93% |
| Operating Margin (TTM) | -2.59% |
| Diluted EPS (TTM) | -0.920 |
| Quarterly Revenue Growth (YOY) | 21.60% |
| Total Debt/Equity (MRQ) | 51.82% |
| Current Ratio (MRQ) | 1.04 |
| Operating Cash Flow (TTM) | 134.38 M |
| Levered Free Cash Flow (TTM) | 66.40 M |
| Return on Assets (TTM) | 0.73% |
| Return on Equity (TTM) | -5.78% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | Evolent Health, Inc | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 3.95% |
| % Held by Institutions | 113.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Eventide Asset Management, Llc | 30 Sep 2024 | 3,804,104 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (Oppenheimer, 143.69%) | Buy |
| Median | 18.00 (56.66%) | |
| Low | 15.00 (Needham, 30.55%) | Buy |
| 15.00 (JP Morgan, 30.55%) | Buy | |
| Average | 18.78 (63.45%) | |
| Total | 8 Buy, 1 Hold | |
| Avg. Price @ Call | 12.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 13 Jan 2025 | 20.00 (74.06%) | Buy | 12.39 |
| Citigroup | 10 Jan 2025 | 18.00 (56.66%) | Buy | 12.54 |
| 13 Nov 2024 | 21.00 (82.77%) | Buy | 12.75 | |
| JMP Securities | 10 Jan 2025 | 18.00 (56.66%) | Buy | 12.54 |
| Needham | 10 Jan 2025 | 15.00 (30.55%) | Buy | 12.54 |
| JP Morgan | 22 Nov 2024 | 15.00 (30.55%) | Buy | 11.25 |
| Oppenheimer | 18 Nov 2024 | 28.00 (143.69%) | Buy | 12.35 |
| 08 Nov 2024 | 34.00 (195.91%) | Buy | 13.36 | |
| RBC Capital | 12 Nov 2024 | 20.00 (74.06%) | Buy | 14.44 |
| Barclays | 11 Nov 2024 | 19.00 (65.36%) | Buy | 15.13 |
| Stephens & Co. | 08 Nov 2024 | 16.00 (39.25%) | Hold | 13.36 |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Dec 2024 | Announcement | Evolent announces Dr. Von Nguyen as incoming Chief Medical Officer, effective January 1 |
| 07 Nov 2024 | Announcement | Humana and Evolent Expand Partnership to Enhance Oncology Care |
| 07 Nov 2024 | Announcement | Evolent Announces Third Quarter 2024 Results |
| 22 Oct 2024 | Announcement | Define Ventures Appoints Bruce Broussard as Venture Partner |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |